OXC-201 also granted ODD by the FDA
Stockholm, 15th September 2026
Oxcia AB today announces that the company’s drug candidate OXC-201 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF). The announcement follows the earlier positive decision from the European Medicines Agency (EMA) only a few weeks ago.
The FDA’s decision is an important milestone for Oxcia’s OXC-201 program and underscores the significant medical need for new treatment options for patients with IPF, a serious, progressive and life-threatening lung disease